Eloralintide 10mg - 10 Vials (KIT)

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Eloralintide (also known as LY3849891) is an experimental peptide-based medication being developed for weight management and metabolic health.

Unlike Tirzepatide and Retatrutide, Eloralintide works primarily by targeting the amylin receptor pathway.

Eloralintide is an amylin analogue. Amylin is a hormone naturally released alongside insulin after eating.

It may help by:

•Reducing appetite – Helps regulate hunger signals.

•Increasing fullness – May make you feel satisfied for longer.

•Reducing food intake – May reduce overall calorie consumption.

•Supporting weight loss – Being investigated as a potential obesity treatment.

•Metabolic regulation – May influence glucose and appetite-related pathways.

Reported side effects include:

Nausea.

Fatigue.

Headaches.

Reduced appetite.

Vomiting.

Injection-site reactions.

Eloralintide remains investigational and is undergoing Phase 3 clinical trials. It is not an approved weight-loss medication in Australia.